{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:21:40Z","timestamp":1775845300417,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-023-00886-9","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T08:02:36Z","timestamp":1691654556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Incorporating digitally derived endpoints within clinical development programs by leveraging prior work"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2563-7581","authenticated-orcid":false,"given":"Amy","family":"Bertha","sequence":"first","affiliation":[]},{"given":"Rinol","family":"Alaj","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6143-170X","authenticated-orcid":false,"given":"Imein","family":"Bousnina","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1190-4403","authenticated-orcid":false,"given":"Megan K.","family":"Doyle","sequence":"additional","affiliation":[]},{"given":"Danielle","family":"Friend","sequence":"additional","affiliation":[]},{"given":"Rasika","family":"Kalamegham","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-8555","authenticated-orcid":false,"given":"Lauren","family":"Oliva","sequence":"additional","affiliation":[]},{"given":"Igor","family":"Knezevic","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Kramer","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-9252","authenticated-orcid":false,"given":"Hans-Peter","family":"Podhaisky","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3556-1804","authenticated-orcid":false,"given":"Sven","family":"Reimann","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"886_CR1","unstructured":"U.S. Food and Drug Administration. Draft Guidance for Industry: Investigators, and Other Stakeholders. Digital Health Technologies for Remote Data Acquisition in Clinical Investigations (2021) Guidance for Industry (fda.gov)."},{"key":"886_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41746-020-0260-4","volume":"3","author":"J Goldsack","year":"2020","unstructured":"Goldsack, J. et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). npj Digit. Med. 3, 55 (2020).","journal-title":"npj Digit. Med."},{"key":"886_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000518024","volume":"5","author":"M Crouthamel","year":"2021","unstructured":"Crouthamel, M. et al. Developing a novel measurement of sleep in rheumatoid arthritis: study proposal for approach and considerations. Digit Biomark. 5, 191\u2013205 (2021).","journal-title":"Digit Biomark."},{"key":"886_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/cts.12602","volume":"12","author":"E Izmailova","year":"2019","unstructured":"Izmailova, E. et al. Evaluation of wearable digital devices in a phase I clinical trial. Clin. Transl. Sci. 12, 247\u2013256 (2019).","journal-title":"Clin. Transl. Sci."},{"key":"886_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/cts.12865","volume":"14","author":"A Godfrey","year":"2021","unstructured":"Godfrey, A. et al. Fit-for-purpose biometric monitoring technologies: leveraging the laboratory biomarker experience. Clin. Transl. Sci. 14, 62\u201374 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"886_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000500413","volume":"3","author":"A Coravos","year":"2019","unstructured":"Coravos, A. et al. Digital medicine: a primer on measurement. Digit Biomark. 3, 31\u201371 (2019).","journal-title":"Digit Biomark."},{"key":"886_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41746-020-0237-3","volume":"3","author":"A Coravos","year":"2020","unstructured":"Coravos, A. et al. Modernizing and designing evaluation frameworks for connected sensor technologies in medicine. npj Digit. Med. 3, 37 (2020).","journal-title":"npj Digit. Med."},{"key":"886_CR8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/mds.27577","volume":"34","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Use digital sensor and deep learning to evaluate motor performance in the D1PAM (LY3154207) phase 1B Parkinson\u2019s disease clinical trial [abstract]. Mov Disord. 34, 58 (2019).","journal-title":"Mov Disord."},{"key":"886_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000512500","volume":"4","author":"D Stephenson","year":"2020","unstructured":"Stephenson, D. et al. Precompetitive consensus building to facilitate the use of digital health technologies to support parkinson disease drug development through regulatory science. Digit Biomark. 4, 28\u201349 (2020).","journal-title":"Digit Biomark."},{"key":"886_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41746-023-00790-2","volume":"6","author":"S Colloud","year":"2023","unstructured":"Colloud, S. et al. Evolving regulatory perspectives on digital health technologies for medicinal product development. npj Digit. Med. 6, 56 (2023).","journal-title":"npj Digit. Med."},{"key":"886_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s43441-023-00535-z","volume":"57","author":"L Gelis","year":"2023","unstructured":"Gelis, L., Stoeckert, I. & Podhaisky, H.-P. Digital tools \u2013 regulatory considerations for application in clinical trials. Ther. Innov. Regul. Sci. 57, 769\u2013782 (2023).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"886_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000529878","volume":"7","author":"B Perry","year":"2023","unstructured":"Perry, B. et al. How much evidence is enough? research sponsor experiences seeking regulatory acceptance of digital health technology-derived endpoints. Digit Biomark. 7, 45\u201353 (2023).","journal-title":"Digit Biomark."},{"key":"886_CR13","unstructured":"U.S Food and Drug Administration. Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products (2017)."},{"key":"886_CR14","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Critical Path Innovation Meetings (2015) Critical Path Innovation Meetings Guidance for Industry (fda.gov)."},{"key":"886_CR15","unstructured":"U.S. Food and Drug Administration. Guidance for Industry and FDA Staff: Qualification Process for Drug Development Tools (2020) Guidance for Industry (fda.gov)."},{"key":"886_CR16","unstructured":"U.S. Food and Drug Administration. Innovation Science and Technology Approaches for New Drugs (ISTAND) Pilot Program [Internet] (2023)."},{"key":"886_CR17","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet] Silver Spring (MD) 2016."},{"key":"886_CR18","unstructured":"U.S. Food and Drug Administration. Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders: Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for Purpose Clinical Outcome Assessments (2022)."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00886-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00886-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00886-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T22:20:44Z","timestamp":1700259644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00886-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["886"],"URL":"https:\/\/doi.org\/10.1038\/s41746-023-00886-9","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing non-financial interests but the following competing financial interests. R.A. is an employee and shareholder of Regeneron. I.B. and R.K. are employees and shareholders of F. Hoffmann-La Roche. M.K.D. is an employee and shareholder of Amgen. D.F. is an employee and shareholder of Janssen. L.O. is an employee and shareholder of Biogen. I.K. and H.-P.P. are employees and shareholders of Bayer. A.B., F.K., and S.R. are employees of Bayer. The views in this publication are that of the authors and do not express the position of our respective companies on the topics discussed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}